The spike protein CoV-2 S-2P, which was created by the U.S. National Institutes of Health, adjuvanted with the TLR-4-agonist Sigma Adjuvant System, which are TLR-4 agonists that induce T-cell activation, generates neutralizing antibody titers in a pseudovirus neutralization assay and a plaque reduction neutralization titer (PRNT) assay. The immunization also produced a balanced T-helper type 1 (Th1)/Th2 cell response, according to a preclinical report published June 11 in bioRxiv.

The research affirms Oragenics' development strategy with its lead vaccine candidate, Terra CoV2, according to the firm. The vaccine is in development and phase I human clinical studies are expected to begin in early 2021.

NIH forms COVID-19 clinical trials network
The National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH), has established a new clinical trials...

Regeneron begins COVID-19 antibody treatment phase III trial
Regeneron Pharmaceuticals has begun adaptive late-stage phase III clinical trials evaluating its antibody cocktail, REGN-COV2, for the treatment and prevention...

Would infecting healthy people with SARS-CoV-2 speed the race to a vaccine?
Could the race to develop a vaccine for SARS-CoV-2 be sped up if researchers were able to study the virus in healthy individuals? And how could such research...

Moderna moves COVID-19 vaccine to late-stage clinical trial
Moderna has finalized phase III clinical study protocols for its mRNA-1273 COVID-19 vaccine candidate in coordination with the U.S. Food and Drug Administration...

NIH researchers investigate virulence of SARS-CoV-2 virus
What makes the SARS-CoV-2 virus so virulent? Researchers from the U.S. National Institutes of Health (NIH) analyzed the genomics of the virus -- and compared...